PROTECTING YOUR RIGHT TO MEDICINES AND MEDICAL DEVICES
Monday, 03 August 2020

There are various other avenues which allow for review of applications for registration to be concluded faster as well as allow for marketing of products in the whole region. These include the Expedited review procedure, WHO Prequalification Collaborative registration procedure, and ZAZIBONA.

  1. Expedited or “Fast-track” Registration Procedure

***First call for submission of applications for registration of medicines under the expedited review pathway in 2019 has been published in Circular 08/2019***

The Authority developed a separate channel for expedited reviews, which should not affect timely review of other applications. Finalisation of the application within 6 months of MCAZ time is guaranteed with this pathway.

More resources are outlaid towards processing applications submitted through the expedited review pathway thus higher fees are prescribed in the current fee schedule.

The following fees are applicable for applications using this pathway:
$4 500 excl. VAT per product for New Chemical Entities

$4 000 excl. VAT per product for generic products

$3 000 excl. VAT per product for line extensions

When submitting applications for registration under the expedited review pathway, applicants should follow steps 1 to 3 described under ‘How to register Conventional medicines’, taking note to indicate the registration pathway as ‘expedited’ in the EVR Quotation Confirmation Form.

  1. WHO Collaborative Registration Procedure

Since June 2012, MCAZ has been participating in the WHO Collaborative Registration Procedure for prequalified products. This collaborative procedure serves to facilitate and accelerate registration of products which have already been assessed and prequalified by WHO Prequalification Team-Medicines (WHO/PQTm). All applicants with WHO prequalified products are encouraged to use this route. With this pathway, finalisation of the application within 90 days of MCAZ time is guaranteed.

A fee of $4 000 excl. VAT per product is charged for applications considered under this procedure.

In the event that an applicant wishes to have an application which is already pending with the MCAZ considered under the WHO collaborative procedure, the applicant should pay a top up fee of $ 1 500 excl. VAT and submit an updated dossier which is in line with that submitted and approved by WHO/PQTm

Applicants wishing to use this route should:

  1. Notify WHO PQ of their intention to use this procedure for registration of a particular product as outlined on the WHO PQ website (Click here)
  2. Follow steps 1 to 3 described under ‘How to register Conventional medicines’, taking note to indicate the registration pathway as ‘WHO Collaborative Procedure’ in the EVR Quotation Confirmation Form.

It is important to note that the approval of the product using this route is based on the WHO prequalification status of the product, therefore, the technical contents of the dossier submitted to Zimbabwe should be exactly similar to that submitted and approved by WHO/PQTm; in addition to Zimbabwe specific requirements on the application form, samples and labelling.

  1. ZAZIBONA

ZAZIBONA is a SADC collaborative registration initiative among the five actively participating national medicines regulatory authorities (NMRAs) in Botswana, Namibia, Zambia, Zimbabwe and South Africa. Active participation in joint review process will be extended to the remaining nine SADC Member States. The objective is to facilitate access to good quality medicines through work-sharing in assessment of applications for registration and inspection of manufacturing and testing facilities. Products that meet the assessment criteria are then granted registration in the participating countries. Where countries agree that it is necessary, variations to the products which have been registered under this collaboration may be handled through the same process.

The ZAZIBONA collaboration does not replace the need to submit applications for registration in participating countries in line with national requirements, and final national registration decisions are the responsibility of individual participating authorities. Both new applications and applications in the pipeline are eligible for consideration under the procedure provided that the product application has been submitted to at least two of the participating countries and in the CTD format.

Applicants interested in having their products assessed under the ZAZIBONA initiative should follow steps 1 to 3 described under ‘How to register Conventional medicines’, taking note to indicate the registration pathway as ‘ZAZIBONA’ in the EVR Quotation Confirmation Form. More information on the ZaZiBoNa procedure can be requested from the following email, This email address is being protected from spambots. You need JavaScript enabled to view it..

 

Latest News

Draft Medicines and Allied Substances Control (Blood and Blood Components) Regulations

26 June 2020
Draft Medicines and Allied Substances Control (Blood and Blood Components) Regulations

 The draft Blood and Blood Components Regulations are now available Please note that this is a DRAFT  that has been uploaded to obtain comments from stakeholders before the regulations are...

Medical Product Alert ; Falsified medical products, including in vitro diagnostics, that claim to prevent, detect, treat or cure COVID-19

06 April 2020
Medical Product Alert ; Falsified medical products, including in vitro diagnostics, that claim to prevent, detect, treat or cure COVID-19

  This Medical Product Alert warns consumers, healthcare professionals, and health authorities against a growing number of falsified medical products that claim to prevent, detect, treat orcure COVID-19.   Medical...

Draft SADC Variations Guidelines

20 March 2020

Draft SADC Variations Guidelines are now available  Click the following links to download the guidelines and the comments sheet Draft SADC Variations Guidelines Draft SADC Variations Guidelines Comments Sheet

Code of Ethics

22 August 2019
Code of Ethics

  In pursuit of promoting high ethical standards, the Authority has formulated a Code of Ethics for its employees and members of the Authority .The Authority believes that high ethical...

SADC Guideline on Product Information and Labeling

10 July 2019
SADC Guideline on Product Information and Labeling

  Southern African Development Community (SADC), as a region has harmonized medicines registration guidelines in the common technical document (CTD) format that were approved in January 2015. Nevertheless, the harmonization...

Careers @ MCAZ

30 October 2018

JOB ADVERTISEMENT:  DIRECTOR-GENERAL, GRADE F2  The Medicines Control Authority of Zimbabwe (MCAZ) is inviting applications from suitably qualified, honest, self-motivated and experienced applicants for the following vacant position: Director-General X...